Document is current
Any future updates will be listed below
-
Authors
Fleischer, Anna
Zapf, Larissa
Allgaier, Johannes
Jordan, Karin
Gelbrich, Götz
Pryss, Rüdiger
Schobel, Johannes
Bittrich, Max
Einsele, Hermann
Kortüm, Martin
Maatouk, Imad
Weinhold, Niels
Rasche, Leo
-
Funding
Funding for this research was provided by:
Federal Ministry of Education and Research (BMBF O1KD 1906)
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 24 May 2023
Accepted: 5 July 2023
First Online: 19 July 2023
Declarations
:
: KJ reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda) and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm and Voluntis HE reports personal fees from: Janssen,Celgene/BMS, Amgen, GSK, Sanofi: Consultancy, Honoraria, Research, NW: Sanofi: Honoraria. AF: fees for advisory board membership from GSK, speaker training BMS, LR personal fees from: Janssen,Celgene/BMS, Amgen, GSK, Sanofi, Pfizer: Consultancy, Honoraria. The remaining authors report no conflict of interests.
: The study was approved by the ethics committee of Würzburg (AZ 270/20).
: Only patients who were able to give informed consent were included.
: All included patients gave their consent for publication of the collected data.
